|

Chemotherapy Drugs, Cancer Clinical Trials

3 actively recruiting trials

Also known as: GenesWell™ BCT (analysis genomic risk), Immunotherapy Antibodies, Cancer

Pipeline

Phase 1/2: 1

Top Sponsors

  • The Second Hospital of Shandong University1
  • Shaare Zedek Medical Center1
  • Gencurix, Inc.1

Indications

  • Cancer3
  • Breast Cancer2
  • Early Hormone Receptor-positive Breast Cancer1
  • Adjuvant1
  • GastroEsophageal Cancer1

Other3 trials

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
N/A
Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy
N/A
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.